GSK糖尿病新药albiglutide结果喜忧参半

GSK公司日前公布了其研发的GLP-1类糖尿病药物albiglutide的相关研究报告。研究数据显示，对比Merck公司的Januvia和Sanofi公司的Amaryl，该种药物能够更有效的降低血糖。但数据同时显示其肠胃副反应的风险也有所增高

详细英文报道：

As has often been the case with GlaxoSmithKline's ($GSK) candidate albiglutide, a late-stage study in diabetics taking the drug and metformin offered some upbeat and downbeat data. On the experimental drug, patients had greater reductions in blood sugar than those on Merck's ($MRK) Januvia or Sanofi's ($SNY) Amaryl, Bloomberg reported. Yet with benefits came the downside of increased gastrointestinal side effects of albiglutide in GSK's Harmony 3 study. The London-based drug giant's once-weekly therapy had previously fallen short of blood-sugar control when compared with Novo Nordisk's ($NVO) GLP-1 standout Victoza, and that makes the safety of albiglutide one of its potential distinguishing factors among several marketed drugs in the class. Patrick Vallance, head of pharma research and development at Glaxo, told the news wire that the GLP-1 field is "crowded." Nevertheless, albiglutide is among a bevy of drug candidates in GSK's late-stage pipeline, which execs have hailed as evidence that their R&D mainframe is operating smoothly after a reboot several years ago.